Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients
Purpose
To evaluate the use of Life2000® Ventilator, a novel proportional open ventilation system in critical care use of acute onset of respiratory failure (ARF) and mild to moderate forms of acute respiratory distress syndrome (ARDS) in COVID-19 patients and its ability to provide effective ventilatory benefits and or delay patients from progressing to more aggressive forms of invasive mechanical ventilation (IMV).
Conditions
- Acute Respiratory Failure
- Covid19
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Patients who meet all of the following inclusion criteria and no
Exclusion Criteria
will be included in the study: - A diagnosed or suspected COVID-19 patient requiring non-invasive ventilatory support and admitted to hospital - PaO2/FiO2 ≤ 300 (corrected for altitude) - RR ≤ 30/min during early use of oxygen - Adults of 18 years and older - Provision of written informed consent to participate in study by subject or legal representative. Exclusion Criteria: Patients who meet one or more of the following exclusion criteria will not be eligible for the study: - Patients under the age of 18 - Patients who are not diagnosed or suspected of having an acute COVID-19 illness - Patients who do not require non-invasive ventilatory interventions, PaO2/FiO2 > 300 (corrected for altitude) and tolerating supplemental oxygen with SpO2 saturations ≥ 92%. - Patients who require immediate IMV upon admission or have a RR > 30/min on early oxygen intervention. - Thoracoabdominal desynchrony and paradoxical breathing at admission - Patients in immediate need of or on vasopressors upon ICU admission - Patients or legal representatives who are unwilling or unable to provide written consent.
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Single Group Assignment
- Intervention Model Description
- Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device. POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment. The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded.
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Life2000® Ventilator |
Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device. |
|
|
No Intervention Control Group |
Subjects in the control group will be identified from the population of patients previously admitted to the study site with COVID-19 infection who required non-invasive oxygen therapy with HFNC but were not treated with NIV therapy. Subject data will be collected retrospectively from the medical record. |
|
Recruiting Locations
Bloomington, Minnesota 55425
Jonathan Shelver, MD
More Details
- NCT ID
- NCT04581161
- Status
- Unknown status
- Sponsor
- Hill-Rom